#India's #pharmasector is projected to grow 8-10% this fiscal, with exports accounting for 53% of #revenue and steady domestic demand. Operating margins are expected to improve to 22.5% in FY25, supported by easing #US pricing pressures and stable input costs. Chronic therapies drive domestic growth.